[go: up one dir, main page]

AR114086A2 - Polvos para reconstitución - Google Patents

Polvos para reconstitución

Info

Publication number
AR114086A2
AR114086A2 ARP190100128A ARP190100128A AR114086A2 AR 114086 A2 AR114086 A2 AR 114086A2 AR P190100128 A ARP190100128 A AR P190100128A AR P190100128 A ARP190100128 A AR P190100128A AR 114086 A2 AR114086 A2 AR 114086A2
Authority
AR
Argentina
Prior art keywords
reconstitution
powders
refers
water soluble
soluble polymers
Prior art date
Application number
ARP190100128A
Other languages
English (en)
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR114086(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of AR114086A2 publication Critical patent/AR114086A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se refiere a polvos para reconstitución que comprenden el NNRTI TMC278 disperso en ciertos polímeros solubles en agua, que puede aplicarse en el tratamiento contra la infección por HIV.
ARP190100128A 2007-03-14 2019-01-21 Polvos para reconstitución AR114086A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104082 2007-03-14

Publications (1)

Publication Number Publication Date
AR114086A2 true AR114086A2 (es) 2020-07-22

Family

ID=38055251

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101032A AR065720A1 (es) 2007-03-14 2008-03-13 Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ARP190100128A AR114086A2 (es) 2007-03-14 2019-01-21 Polvos para reconstitución

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080101032A AR065720A1 (es) 2007-03-14 2008-03-13 Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.

Country Status (18)

Country Link
US (1) US8916558B2 (es)
EP (1) EP2043608B1 (es)
JP (1) JP5554571B2 (es)
KR (1) KR101580297B1 (es)
CN (1) CN101636149B (es)
AP (1) AP2964A (es)
AR (2) AR065720A1 (es)
AU (1) AU2008225774B2 (es)
BR (1) BRPI0808897B8 (es)
CA (1) CA2676981C (es)
CL (1) CL2008000746A1 (es)
ES (1) ES2535162T3 (es)
IL (1) IL199874A (es)
MX (1) MX2009009743A (es)
RU (1) RU2477133C2 (es)
TW (1) TWI494133B (es)
WO (1) WO2008110619A1 (es)
ZA (1) ZA200906344B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
SI2696848T1 (sl) 2011-04-15 2020-10-30 Janssen Pharmaceutica N.V. Liofilizirane zdravilne nanosuspenzije
WO2014048783A1 (en) * 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
CN114126655A (zh) * 2019-07-03 2022-03-01 爱尔兰詹森科学公司 用利匹韦林治疗儿科患者的hiv的方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
TW202408580A (zh) * 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(二)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
KR0172134B1 (ko) 1990-07-19 1999-02-01 오오쓰까 아끼히코 고형 제제
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CA2383233C (en) 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
EP1267879A2 (en) 2000-03-30 2003-01-02 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
AU2003266413B2 (en) 2002-08-09 2009-04-02 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2003278766A1 (en) 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ATE361059T1 (de) 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
WO2004046143A1 (en) 2002-11-15 2004-06-03 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
KR20110132482A (ko) 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AR049297A1 (es) * 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN104586850A (zh) 2004-09-02 2015-05-06 詹森药业有限公司 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP2008538754A (ja) 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
AR056652A1 (es) * 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
PL1981506T6 (pl) 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
MX2008015686A (es) 2006-06-06 2009-01-12 Tibotec Pharm Ltd Procedimiento para preparar formulaciones secadas por aspersion de etravirina.
SI3366278T1 (sl) 2006-06-23 2024-12-31 Janssen Sciences Ireland Unlimited Company Vodne suspenzije tmc278
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
DK2175857T3 (da) 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP2358198A4 (en) 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Also Published As

Publication number Publication date
IL199874A0 (en) 2010-04-15
BRPI0808897B1 (pt) 2020-10-20
US20100120795A1 (en) 2010-05-13
AU2008225774B2 (en) 2014-04-10
AU2008225774A1 (en) 2008-09-18
RU2009137911A (ru) 2011-04-20
KR20090119964A (ko) 2009-11-23
US8916558B2 (en) 2014-12-23
ES2535162T3 (es) 2015-05-05
KR101580297B1 (ko) 2015-12-24
BRPI0808897B8 (pt) 2021-05-25
IL199874A (en) 2016-02-29
JP5554571B2 (ja) 2014-07-23
RU2477133C2 (ru) 2013-03-10
TW200911303A (en) 2009-03-16
CA2676981C (en) 2015-01-13
BRPI0808897A2 (pt) 2014-09-02
TWI494133B (zh) 2015-08-01
CN101636149B (zh) 2014-08-06
AP2964A (en) 2014-09-30
EP2043608A1 (en) 2009-04-08
AP2009004969A0 (en) 2009-10-31
WO2008110619A1 (en) 2008-09-18
EP2043608B1 (en) 2015-01-21
AR065720A1 (es) 2009-06-24
MX2009009743A (es) 2009-09-23
CL2008000746A1 (es) 2008-09-22
CN101636149A (zh) 2010-01-27
CA2676981A1 (en) 2008-09-18
ZA200906344B (en) 2015-04-29
JP2010520918A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
AR114086A2 (es) Polvos para reconstitución
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
WO2012006538A8 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
BR112013007286A2 (pt) composição polimérica, película e bolsa de autoclave.
ECSP13012382A (es) Composiciones sólidas
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
MX355295B (es) Artículos para el cuidado personal.
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2013001723A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico.
BRPI1007457A2 (pt) Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
ATE496906T1 (de) 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyri inyl-2'-one
CR20110553A (es) Terapia complementaria contra el cáncer
EP2175817A4 (en) ABSORBENT ARTICLE ADHERING TO THE BODY
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
JP2013541099A5 (es)
DOP2010000321A (es) Derivados de iminopirimidina y su uso
BRPI0906168A2 (pt) Membro fêmea para prendedor de laço e gancho, prendedor de laço e gancho empregado em membro fêmea, e artigo absorvente empregando o prendedor de laço e gancho.
BRPI0814576A2 (pt) Item de calçado, e, métodos para preparar um item de calçado, e para aperfeiçoar o conforto de um item de calçado para o usuário.
WO2014179615A3 (en) Biodegradable copolymers, forming and using same
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
AR084487A1 (es) Componente prostesico con una superficie deslizante que contiene un recubrimiento antimicrobiano
WO2008145475A8 (en) Oral care composition

Legal Events

Date Code Title Description
FC Refusal